In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $470.13, denoting a +2.54% move from the preceding trading day.

Vertex Pharmaceuticals is all set to release its fiscal second-quarter earnings next month, and analysts project a robust ...

Morgan Stanley's analyst, Terence Flynn, sticks to his guns with a Hold rating for Vertex Pharmaceuticals, pegging the price ...

The stock's rise snapped a three-day losing streak.

In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV1 and superior in reducing sweat chloride compared to ...

Vertex Pharmaceuticals (VRTX) continues to charm the market, securing a "Moderate Buy" consensus from 28 research firms.

Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...

Vertex Pharmaceuticals (VRTX) announced that Health Canada has granted Marketing Authorization for ALYFTREK, a new triple combination therapy for ...

NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill ...

Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) therapy has been recommended by the National Institute for ...

Vertex Pharmaceuticals (NASDAQ:VRTX) will release its quarterly earnings report on Monday, 2025-05-05. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Vertex ...

Sales of the ground-breaking cystic fibrosis (CF) drug Kaftrio was the main driver behind revenues of a Dublin unit of Vertex Pharmaceuticals surging to $2.63bn (€2.26bn) last year.